The Identification of Immunological Biomarkers in Kidney Cancers
The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an important step forw...
Main Authors: | Antonio Lopez-Beltran, Vanessa Henriques, Alessia Cimadamore, Matteo Santoni, Liang Cheng, Thomas Gevaert, Ana Blanca, Francesco Massari, Marina Scarpelli, Rodolfo Montironi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00456/full |
Similar Items
-
Is There a Role for Immunotherapy in Prostate Cancer?
by: Alessandro Rizzo, et al.
Published: (2020-09-01) -
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
by: Andrea Marchetti, et al.
Published: (2021-06-01) -
Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities
by: Ryan J. King, et al.
Published: (2021-07-01) -
Editorial: Immunological Mechanisms, Biomarkers and Immunotherapies of Alzheimer's Disease
by: Jia-yan Xin, et al.
Published: (2021-09-01) -
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
by: Antonio Lopez-Beltran, et al.
Published: (2021-01-01)